ALK Abello
16.11.2026 13:39:46 CET | Globenewswire | Press release
ALK to present at the Jefferies Global Healthcare Conference in London
ALK to present at the Jefferies Global Healthcare Conference in London
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the company’s president & CEO, Peter Halling, is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference in London taking place from 16 - 19 November 2026 on Wednesday, 18 November 2026, at 10.00 AM GMT / 11.00 AM CET.
A live webcast of the fireside chat will be accessible through this link and available on ALK’s investor site: Investors | ALK, where a recording of the webcast will also be archived after the event.
Representatives of the company will be available for meetings at the conference.
ALK-Abelló A/S
For further information, please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Maiken Riise Andersen, tel. +45 5054 1434
About ALK
ALK is a global specialty pharmaceutical company focused on allergy. ALK's activities cover the entire value chain of developing, sourcing, producing, and marketing a diversified portfolio of products for diagnosing and treating respiratory allergies and severe allergic reactions (anaphylaxis) in both children and adults. Headquartered in Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen (Nasdaq: ALK B). Visit us at www.alk.net.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Bitget Limited16.11.2026 14:00:00 CET | Press release
Bitget Launches rToken Earn, Bringing Onchain Yield to Tokenized ETFs with Bitwise Set to Curate the Strategy
Teva Pharmaceutical Industries Ltd16.11.2026 14:00:00 CET | Press release
U.S. FDA Approves IGALMI® as First At-Home Acute Treatment for Agitation Associated with Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder in Adults
MacuMira Medical Devices Inc.16.11.2026 14:00:00 CET | Press release
MacuMira Receives CE Mark for Its Microcurrent Treatment for Dry AMD
YYForce Inc.16.11.2026 13:30:00 CET | Press release
YYForce Sets Operating Priorities Across AI Workforce, Robotics and Facility Management
Ålandsbanken16.11.2026 13:15:00 CET | Press release
Correction: Bank of Åland Plc: Interim Report for the period January - September 2026
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom